Sheri J Hartman1,2, Sandahl H Nelson1,2, Catherine R Marinac3,4, Loki Natarajan1,2, Barbara A Parker2,5, Ruth E Patterson1,2. 1. Department of Family Medicine and Public Health, UC San Diego, La Jolla, California. 2. UC San Diego Moores Cancer Center, UC San Diego, La Jolla, California. 3. Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 4. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 5. Department of Medicine, UC San Diego, La Jolla, California.
Abstract
OBJECTIVE:Breast cancer survivors experience problems with cognition that interfere with daily life and can last for years. In the general population, obesity and diabetes are risk factors for cognitive decline, and weight loss can improve cognition; however, the impact of intentional weight loss on cancer survivors' cognition has not been tested. We investigated the impact of weight loss and metformin on changes in cognitive function in a sample of breast cancer survivors. METHODS:Overweight/obese postmenopausal breast cancer survivors (n = 333) were randomized to a weight loss intervention versus control and metformin versus placebo in a 2 × 2 factorial design. Outcomes were changes in five cognitive domains from baseline to 6 months measured by objective neurocognitive tests. RESULTS: There were no statistically significant intervention effects for the metformin or weight loss interventions in five neurocognitive domains. Baseline body mass index (BMI) was a significant effect modifier of the changes in verbal functioning for the weight loss (P = 0.009) and metformin interventions (P = 0.0125). These effect modifications were independent of percent weight loss achieved during the 6-month study period. CONCLUSIONS: This randomized controlled trial of weight loss and metformin interventions that examined changes to cognition among breast cancer survivors suggests that these interventions may not improve cognitive functioning among breast cancer survivors in general. However, weight loss may improve verbal functioning among individuals with a higher BMI.
RCT Entities:
OBJECTIVE:Breast cancer survivors experience problems with cognition that interfere with daily life and can last for years. In the general population, obesity and diabetes are risk factors for cognitive decline, and weight loss can improve cognition; however, the impact of intentional weight loss on cancer survivors' cognition has not been tested. We investigated the impact of weight loss and metformin on changes in cognitive function in a sample of breast cancer survivors. METHODS: Overweight/obese postmenopausal breast cancer survivors (n = 333) were randomized to a weight loss intervention versus control and metformin versus placebo in a 2 × 2 factorial design. Outcomes were changes in five cognitive domains from baseline to 6 months measured by objective neurocognitive tests. RESULTS: There were no statistically significant intervention effects for the metformin or weight loss interventions in five neurocognitive domains. Baseline body mass index (BMI) was a significant effect modifier of the changes in verbal functioning for the weight loss (P = 0.009) and metformin interventions (P = 0.0125). These effect modifications were independent of percent weight loss achieved during the 6-month study period. CONCLUSIONS: This randomized controlled trial of weight loss and metformin interventions that examined changes to cognition among breast cancer survivors suggests that these interventions may not improve cognitive functioning among breast cancer survivors in general. However, weight loss may improve verbal functioning among individuals with a higher BMI.
Authors: Nananda F Col; Leslie Ochs; Vicky Springmann; Aaron K Aragaki; Rowan T Chlebowski Journal: Breast Cancer Res Treat Date: 2012-07-31 Impact factor: 4.872
Authors: Vincent Koppelmans; Michiel B de Ruiter; Fedde van der Lijn; Willem Boogerd; Caroline Seynaeve; Aad van der Lugt; Henri Vrooman; Wiro J Niessen; Monique M B Breteler; Sanne B Schagen Journal: Breast Cancer Res Treat Date: 2011-12-29 Impact factor: 4.872
Authors: Sophie Lauzier; Elizabeth Maunsell; Mélanie Drolet; Douglas Coyle; Nicole Hébert-Croteau; Jacques Brisson; Benoît Mâsse; Belkacem Abdous; André Robidoux; Jean Robert Journal: J Natl Cancer Inst Date: 2008-02-26 Impact factor: 13.506
Authors: Mark A Espeland; José A Luchsinger; Laura D Baker; Rebecca Neiberg; Steven E Kahn; Steven E Arnold; Rena R Wing; George L Blackburn; George Bray; Mary Evans; Helen P Hazuda; Robert W Jeffery; Valerie M Wilson; Jeanne M Clark; Mace Coday; Kathryn Demos-McDermott; John P Foreyt; Frank Greenway; James O Hill; Edward S Horton; John M Jakicic; Karen C Johnson; William C Knowler; Cora E Lewis; David M Nathan; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; Thomas A Wadden; Stephen R Rapp Journal: Neurology Date: 2017-04-26 Impact factor: 9.910
Authors: Hadeer Ehab Barakat; Raghda R S Hussein; Ahmed Abdullah Elberry; Mamdouh Ahmed Zaki; Mamdouh Elsherbiny Ramadan Journal: Sci Rep Date: 2022-05-10 Impact factor: 4.996